#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	4488	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2471	541.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1858	1858	T	659	T	583	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	4488	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2471	541.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1592	1592	C	651	C	571	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	4488	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2471	541.5	0	HET	.	.	.	A922G	.	922	922	A	1330	1330	A	654	A,G	318,279	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6972	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3931	532.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1837	1837	A	620	A,C	560,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6972	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3931	532.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2471	2471	C	604	C	529	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6972	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3931	532.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2545	2545	A	612	A	533	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6972	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3931	532.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3097	3097	C	593	C	521	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6972	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3931	532.2	0	HET	.	.	.	C709T	.	709	709	C	1209	1209	C	595	C,T	381,138	.	.
folP.WHO_N_01367c	folP.WHO_N_01367c	1	1	27	724	folP	852	852	99.88	folP.l6.c4.ctg.1	2169	100.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1564	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3721	126.2	1	SNP	p	S91F	0	.	.	271	273	TCC	689	691	TCC	129;129;129	T;C;C	114;115;113	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1564	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3721	126.2	1	SNP	p	D95N	0	.	.	283	285	GAC	701	703	GAC	127;127;128	G;A;C	115;112;117	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1564	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3721	126.2	1	SNP	p	D95G	0	.	.	283	285	GAC	701	703	GAC	127;127;128	G;A;C	115;112;117	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	646	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1605	120.8	0	.	p	.	0	A39T	NONSYN	115	117	GCC	587	589	ACC	166;167;167	A;C;C	144;147;146	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	646	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1605	120.8	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	785	787	CAC	182;181;183	C;A;C	160;154;158	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	646	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1605	120.8	0	.	p	.	0	E117K	NONSYN	349	351	GAA	821	823	AAA	184;185;183	A;A;A	157;159;158	.	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	539	646	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1605	120.8	1	SNP	p	G45D	0	.	.	133	135	GGC	605	607	GGC	166;167;167	G;G;C	144;146;147	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	480	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c17.ctg.1	1259	114.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1362	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3234	126.2	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1730	1732	GCA	128;128;126	G;C;A	109;109;108	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1362	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3234	126.2	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2213	2215	ATT	171;171;173	A;T;T	150;149;157	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1362	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3234	126.2	1	SNP	p	D86N	0	.	.	256	258	GAC	683	685	GAC	156;156;157	G;A,C;C	135;132,1;134	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1362	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3234	126.2	1	SNP	p	S87R	0	.	.	259	261	AGT	686	688	AGT	156;155;155	A;G;T,G	131;133;132,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1362	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3234	126.2	1	SNP	p	S87W	0	.	.	259	261	AGT	686	688	AGT	156;155;155	A;G;T,G	131;133;132,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1362	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3234	126.2	1	SNP	p	S87I	0	.	.	259	261	AGT	686	688	AGT	156;155;155	A;G;T,G	131;133;132,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	1362	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3234	126.2	1	SNP	p	S88P	0	.	.	262	264	TCC	689	691	TCC	155;155;156	T;C;C	132;132;133	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1330	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2934	135.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1651	1653	GGC	180;179;178	G,T;G;C,A	157,1;157;153,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.002	penA.22.002	1	1	27	1222	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2788	131.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1426	1428	GCA	171;172;171	G;C,A;A	145;146,1;142	penA.22.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1222	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2788	131.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1429	1431	ATC	168;169;170	A;T;C	144;145;148	penA.22.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1222	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2788	131.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1441	1443	GTG	168;170;171	G;T;G	146;148;146	penA.22.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1222	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2788	131.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1441	1443	GTG	168;170;171	G;T;G	146;148;146	penA.22.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1222	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2788	131.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1945	1947	ACC	175;177;178	A;C;C	152;156;154	penA.22.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1222	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2788	131.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1999	2001	GCG	168;170;169	G;C;G	144;137;136	penA.22.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1222	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2788	131.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1999	2001	GCG	168;170;169	G;C;G	144;137;136	penA.22.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1222	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2788	131.4	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2122	2124	GGT	159;159;159	G,C;G;T,G,C	133,1;138;133,1,1	penA.22.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1222	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2788	131.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2131	2133	GGC	162;162;162	G;G;C	135;138;140	penA.22.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.002	penA.22.002	1	1	27	1222	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2788	131.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2149	2151	CCG	163;163;160	C;C;G	133;135;133	penA.22.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1462	ponA	2397	2397	99.96	ponA.l15.c17.ctg.1	3315	132.3	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1725	1727	CTG	150;150;153	C;T;G	126;126;129	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	776	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2167	107.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	771	771	C	130	C	118	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	786	9.9	0	.	p	.	0	H217N	NONSYN	649	651	CAT	524	526	AAT	9;8;8	A;A;T	7;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	786	9.9	0	.	p	.	0	D218N	NONSYN	652	654	GAT	527	529	AAT	8;8;8	A;A;T	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	786	9.9	0	.	p	.	0	V226A	NONSYN	676	678	GTA	551	553	GCA	6;6;6	G;C;A	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	786	9.9	0	.	p	.	0	.	MULTIPLE	700	702	ACT	574	576	GTA	4;4;4	G;T;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	786	9.9	0	.	p	.	0	S236N	NONSYN	706	708	AGC	580	582	AAC	3;3;3	A;A;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	786	9.9	0	.	p	.	0	.	MULTIPLE	709	711	AAC	584	589	TGGCAT	3;3;3;3;3;3	T;G;G;C;A;T	3;3;3;3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	786	9.9	0	.	p	.	0	D238A	NONSYN	712	714	GAT	590	592	GCT	3;3;3	G;C;T	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	786	9.9	0	.	p	.	0	V258L	NONSYN	772	774	GTA	650	652	TTA	3;3;3	T;T;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	786	9.9	0	.	p	.	0	Y273R	NONSYN	817	819	TAT	695	697	CGT	4;4;4	C;G;T	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	786	9.9	0	.	p	.	0	D274S	NONSYN	820	822	GAT	698	700	AGT	4;4;4	A;G;T	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	74	porB1a	984	287	90.38	porB1a.l6.c30.ctg.1	786	9.9	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	707	709	TAC	4;4;4	T;A;C	3;3;3	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	778	porB1b	1035	1035	97.71	porB1b.l15.c4.ctg.1	1862	123.8	0	.	p	.	0	E38G	NONSYN	112	114	GAA	605	607	GGA	156;156;155	G;G;A	131;130;131	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	778	porB1b	1035	1035	97.71	porB1b.l15.c4.ctg.1	1862	123.8	0	.	p	.	0	G46S	NONSYN	136	138	GGC	629	631	AGC	166;166;164	A;G;C	139;138;133	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	778	porB1b	1035	1035	97.71	porB1b.l15.c4.ctg.1	1862	123.8	0	.	p	.	0	V98I	NONSYN	292	294	GTC	785	787	ATC	149;150;150	A;T;C	132;135;136	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	778	porB1b	1035	1035	97.71	porB1b.l15.c4.ctg.1	1862	123.8	0	.	p	.	0	E134K	NONSYN	400	402	GAG	893	895	AAG	145;146;145	A;A;G	125;128;126	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	778	porB1b	1035	1035	97.71	porB1b.l15.c4.ctg.1	1862	123.8	0	.	p	.	0	R143E	NONSYN	427	429	AGA	920	922	GAA	141;142;142	G;A;A	122;120;121	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	778	porB1b	1035	1035	97.71	porB1b.l15.c4.ctg.1	1862	123.8	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1124	1124	T	151	T	129	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	778	porB1b	1035	1035	97.71	porB1b.l15.c4.ctg.1	1862	123.8	1	SNP	p	A121D	0	.	.	361	363	GCC	854	856	GCC	145;146;146	G;C,A;C	127;127,1;125	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	778	porB1b	1035	1035	97.71	porB1b.l15.c4.ctg.1	1862	123.8	1	SNP	p	A121N	0	.	.	361	363	GCC	854	856	GCC	145;146;146	G;C,A;C	127;127,1;125	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2782	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5230	159.7	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2194	2196	CAT	168;168;169	C;A,T;T	149;149,1;151	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	430	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	1313	98.4	1	SNP	p	V57M	0	.	.	169	171	GTG	707	709	GTG	180;180;181	G;T;G	157;159;157	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
